Skip to main content

Parkinson's Disease clinical trials at UC Davis

4 research studies open to eligible people

Showing trials for
  • A Dose Selection Study of Light Therapy for Impaired Sleep in Parkinson’s Disease

    open to eligible people ages 45 years and up

    This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times throughout the day.

    Sacramento, California and other locations

  • A Study of Subcutaneous ND0612 Infusion in Parkinson's Disease

    open to eligible people ages 30-80

    This is a multi-center, randomized, double blind, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR LD/CD. Subjects can continue to an optional open-label extension period for one year; To contact US site near you should go to:

    San Francisco, California and other locations

  • SHINE Study: Testing a New Oral Drug to Treat Parkinson's Disease With Dyskinesia

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18-80

    This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.

    Detroit, Michigan and other locations

  • The PRISM Study is Enrolling People with Early-Stage Parkinson's Disease to Test a Potential New Treatment

    “You Can Make a Difference and Help Accelerate Breakthroughs in Parkinson’s Disease Research!”

    open to eligible people ages 30-80

    This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders. For more information, please visit:

    Sacramento, California and other locations

Last updated: